Aap Implantate AG Reports Earnings Improvement in 2025 and Outlines 2026 Outlook

aap Implantate AG reported an improvement in EBITDA, rising from EUR -0.85 million to EUR -0.64 million for 2025, with trauma business nearing a break-even. Revenue increased by 2% to EUR 12.5 million, despite geopolitical tensions and US tariff policies impacting the market. EMEA remained the largest sales region, with Germany showing a 5% growth. Brazil excelled with over 60% growth in the LATAM region.

The company's gross margin remained steady at 87%. A clinical study on their new antibacterial implants was successfully completed, pending further ethics review. aap plans to introduce new products following MDR certification, aiming for significant earnings contributions from 2027 onwards. For 2026, sales are projected between EUR 11.5 million and EUR 14.5 million, with EBITDA expected to improve to EUR -1.0 million to EUR +1.5 million.